Mei Pharma Inc Cmn (MEIP) 1.76 $MEIP MEI Pharma to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mei Pharma Inc Cmn (MEIP) 1.76 $MEIP

MEI Pharma to Present at Wedbush PacGrow Healthcare Conference
PR Newswire - Wed Aug 10, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 8:00 a.m. Eastern time from Le Parker Meridien in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)

Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases
PR Newswire - Mon Aug 08, 7:00AM CDT
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive licensing, development and commercialization agreement for Pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukemia (AML) and other potential indications. The deal provides the complementary resources from both organizations to rapidly advance Pracinostat into Phase III clinical development and expand into additional indications, including high-risk myelodysplastic syndrome (MDS).
MEIP: 1.76 (+0.02)

MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
PR Newswire - Mon Aug 01, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are greater-than or equal to 75 years of age or unfit for intensive chemotherapy. In addition, agreement has been reached with the FDA on the Company's proposed Phase III study design.
MEIP: 1.76 (+0.02)

MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor
PR Newswire - Wed Apr 20, 7:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced new clinical data from a first-in-human study of MEI Pharma's investigational drug candidate, ME-401, a next generation oral PI3K delta inhibitor. The data, presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, suggest that ME-401 has an excellent pharmacokinetic (PK) and pharmacodynamic (PD) profile and the potential for an improved therapeutic window compared to other PI3K delta inhibitors, including the approved drug idelalisib (marketed as Zydelig®), with a half-life that supports once-daily dosing.
MEIP: 1.76 (+0.02)

MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)

MEI Pharma to Present at Needham Healthcare Conference
PR Newswire - Tue Apr 05, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time from the Westin Grand Central Hotel in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)

MEI Pharma to Present at BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. Eastern time from the Waldorf Astoria New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)

World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.26 (+0.01), MBVX: 5.09 (+0.11), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), BIND: 0.78 (-0.09), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), MRK: 62.98 (+0.08), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), ARRY: 3.50 (-0.02), EXEL: 11.54 (+0.19)

Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), AMPE: 0.85 (-0.01), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), AAAP: 34.63 (+0.22), MACK: 4.53 (-0.06), PGNX: 5.96 (-0.18), BLCM: 17.24 (-0.23), CYCC: 5.71 (unch), RXDX: 5.90 (+0.02), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), JUNO: 28.44 (-0.85), CBLI: 1.86 (-0.13), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)

MEI Pharma elects Christine White, MD as board chair
M2 - Fri Dec 11, 4:16AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) revealed on Thursday that it has appointed Christine White, MD as chairman of the board of directors.
MEIP: 1.76 (+0.02)

MEI Pharma Appoints Dr. Christine White as Chairman of the Board
PR Newswire - Thu Dec 10, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Christine White, M.D., as Chairman of the Board of Directors. Dr. White joined the Company's board in August 2010 and has served as its Lead Director since the retirement of former Chairman, Professor Bryan R.G. Williams, Ph.D., in January 2013.
MEIP: 1.76 (+0.02)

MEI Pharma (MEIP) Worth Watching: Stock Gains 5.4%
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:00AM CST
MEI Pharma (MEIP) was a big mover last session, with its shares rising over 5% on the day.
CORT: 5.31 (-0.04), MEIP: 1.76 (+0.02)

Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 34.77 (+0.09), SPPI: 5.24 (-0.05), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), ONTY: 1.21 (+0.02), NKTR: 18.45 (+0.34), MEIP: 1.76 (+0.02), ATNM: 1.70 (-0.06), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19), NVS: 79.38 (+1.11)

MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
PR Newswire - Mon Dec 07, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The results were presented earlier today at the American Society of Hematology (ASH) Annual Meeting in Orlando. A copy of the presentation is now available at www.meipharma.com.
MEIP: 1.76 (+0.02)

MEI Pharma to Host Annual Meeting of Stockholders
PR Newswire - Mon Nov 23, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Eastern time on Thursday, December 3, 2015, at the offices of Morgan, Lewis & Bockius LLP, located at 101 Park Avenue, New York, NY 10178. Stockholders of record at the close of business on October 7, 2015 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
MEIP: 1.76 (+0.02)

MEI Pharma to Present at Stifel Healthcare Conference
PR Newswire - Wed Nov 11, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 8:00 a.m. Eastern time from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)

MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
PR Newswire - Thu Nov 05, 8:07AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the publication of new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in patients with previously untreated myelodysplastic syndrome (MDS) and elderly patients with acute myeloid leukemia (AML). Results from these studies were recently selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando on December 7, 2015. The abstracts are now available on the ASH website at www.hematology.org.
MEIP: 1.76 (+0.02)

MEI Pharma to Present at 14th Annual BIO Investor Forum
PR Newswire - Mon Oct 19, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that David Urso, JD, Senior Vice President, Corporate Development & General Counsel, will present at the 14th Annual Biotechnology Industry Organization (BIO) Investor Forum on Wednesday, October 21, 2015 at 9:00 a.m. Pacific time from the Parc 55 San Francisco. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)

MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
PR Newswire - Tue Oct 06, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the Company's Phase II clinical studies of Pracinostat in elderly acute myeloid leukemia (AML) and previously untreated myelodysplastic syndrome (MDS) have been selected by the American Society of Hematology (ASH) Program Committee for oral presentation at the 57th ASH Annual Meeting & Exposition in Orlando on December 7, 2015.
MEIP: 1.76 (+0.02)

Strength Seen in MEI Pharma (MEIP): Stock Jumps 11.1%
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:04AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares rise over 11% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Sunrise New Energy Unveils Innovative Solid-State Battery Patent

Updated Category News Views 205

Sunrise New Energy's Patent for Solid-State Battery Innovation Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has made significant strides in energy technology with the announcement of a groundbreaking invention patent for a novel method of creating lithium cerate-coated graphite iron oxide anode material. This development is a significant leap forward in the realm of...

Continue Reading
Leadership Transition at Lykos Therapeutics Following FDA Setback

Updated Category News Views 103

Leadership Change at Lykos Therapeutics After FDA Setback Amy Emerson has resigned as CEO of Lykos Therapeutics following significant regulatory hurdles. This change comes after the Food and Drug Administration (FDA) recently rejected the company's application for its ecstasy-based therapy aimed at treating post-traumatic stress disorder (PTSD). Consequences of FDA...

Continue Reading
RADCOM to Showcase Innovations at Upcoming Growth Conference

Updated Category News Views 228

RADCOM to Showcase Innovations at Growth Conference RADCOM Ltd. (Nasdaq: RDCM) is gearing up for a prominent appearance at the 28th Annual Needham Growth Conference. The conference will take place at the esteemed Lotte NY Palace Hotel, where the company is excited to highlight its cutting-edge technological advancements. Leadership Team Participation At this significant...

Continue Reading
Shoppers Prioritize Savings Over Convenience, Survey Reveals

Updated Category News Views 81

New Insights into Consumer Preferences During Holidays A recent survey conducted by GoDaddy sheds light on the evolving preferences of consumers as the holiday season approaches. The findings reveal that convenience often takes a backseat to cost savings, which fundamentally impacts how businesses engage with their customers. The Importance of Cost Savings According to...

Continue Reading
Criteo's Insider Trading Insights: What You Need to Know

Updated Category News Views 116

Understanding Recent Insider Trading at Criteo Recently, significant insider trading activity has caught the attention of investors and analysts. Notably, Ryan Damon, Chief Legal Officer at Criteo, made headlines with a prominent stock sale involving his holdings in the company. Insider Sales: A Breakdown During a recent filing, it was disclosed that Ryan Damon sold 3,393...

Continue Reading